In conclusion, low calpain-2 and high calpastatin expression are associated with adverse breast cancer-specific survival in non-inflammatory large but operable breast cancer treated with neoadjuvant chemotherapy, and determining the expression of these important proteins may be of clinical relevance. The gene discussed is CAPN2; the disease is breast cancer.